Skip to content
10-K

Annual Report

ACADIA PHARMACEUTICALS INC ACAD

0000950170-25-029253

← back to feed
Filed
Feb 27, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 18, 2025 166.79M sh
Current Liabilities FY 2024 · Dec 31, 2023 $254.25M
Total Liabilities FY 2024 · Dec 31, 2023 $317.2M
Current Assets FY 2024 · Dec 31, 2023 $616.13M
Total Assets FY 2024 · Dec 31, 2023 $748.96M
Shares Diluted restated FY 2024 · Dec 31, 2022 161.68M sh
Capex FY 2024 · Dec 31, 2022 $0
Operating Cash Flow FY 2024 · Dec 31, 2022 −$114.04M
Cash And Equivalents FY 2024 · Dec 31, 2022 $114.85M
Eps Diluted FY 2024 · Dec 31, 2022 −$1.34
Eps Basic FY 2024 · Dec 31, 2022 −$1.34
Sga Expense FY 2024 · Dec 31, 2022 $369.09M
Rd Expense FY 2024 · Dec 31, 2022 $361.58M
Net Income FY 2024 · Dec 31, 2022 −$215.98M
Operating Income FY 2024 · Dec 31, 2022 −$223.6M
Cost Of Revenue FY 2024 · Dec 31, 2022 $10.17M
Revenue FY 2024 · Dec 31, 2022 $517.24M
Stockholders Equity FY 2024 · Dec 31, 2021 $540.89M